Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > BioSante Pharmaceuticals to Present at the Susquehanna Healthcare Conference

Abstract:
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that Stephen M. Simes, its president and CEO, will present a corporate update and overview at the Susquehanna Financial Group's Second Annual Healthcare Conference, at the W Hotel in New York City. Mr. Simes will present on Wednesday March 5, 2008 at 11:30 a.m. local time. The Susquehanna Conference will feature more than 50 companies presenting to institutional investors, portfolio managers and analysts interested in the biotechnology and pharmaceuticals sectors.

BioSante Pharmaceuticals to Present at the Susquehanna Healthcare Conference

LINCOLNSHIRE, IL | Posted on March 4th, 2008

A live audio webcast of BioSante's presentation at the Susquehanna Conference may be accessed at www.biosantepharma.com/Webcasts.php and a replay will be available at the same link for 60 days.

####

About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver estradiol and testosterone. BioSante's lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Nycomed US, BioSante's licensee. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™).

For more information, please click here

Contacts:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316

www.mckinneychicago.com

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014

President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014

Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014

Air Force’s 30-year plan seeks 'strategic agility' August 1st, 2014

Nanomedicine

Taking the guesswork out of cancer therapy: New molecular test kit predicts patient’s survival and drug response August 1st, 2014

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Announcements

Light pulses control graphene's electrical behavior: Finding could allow ultrafast switching of conduction, and possibly lead to new broadband light sensors August 1st, 2014

President Obama Meets U.S. Laureates of 2014 Kavli Prizes August 1st, 2014

Stanford researchers seek 'Holy Grail' in battery design: Pure lithium anode closer to reality with development of protective layer of interconnected carbon domes August 1st, 2014

Air Force’s 30-year plan seeks 'strategic agility' August 1st, 2014

Events/Classes

International Conference in Nanomaterials and Technologies CNT 2014 August 1st, 2014

Arrowhead to Report Fiscal 2014 Third Quarter Financial Results- Conference Call Scheduled for Tuesday, August 12, 2014 - July 31st, 2014

FLAG-ERA and TNT2014 join efforts: Graphene Networking at its higher level in Barcelona: Encourage the participation in a joint transnational call July 30th, 2014

FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE